Prevention of Legionnaires' disease in transplant recipients: Recommendations for a standardized approach

Transplant Infectious Disease

Volumn 6, Issue 2, 2004, Pages 58-62

  Singh, N ^a   Stout, J E ^a   Yu, Victor L ^a,b  

^a VA Healthcare VISN 4   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Legionella; Legionnaires' disease; Prevention; Transplant

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN A; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOOD GROUP TYPING; COMMUNITY ACQUIRED PNEUMONIA; DISINFECTION; DRINKING BEHAVIOR; EDITORIAL; FLUID INTAKE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY DIAGNOSIS; LEGIONNAIRE DISEASE; PRIORITY JOURNAL; RECIPIENT; WATER SUPPLY;

BACTERIOLOGICAL TECHNIQUES; CROSS INFECTION; DISINFECTION; HEALTH PLANNING GUIDELINES; HOSPITALS; HUMANS; LABORATORIES; LEGIONNAIRES' DISEASE; ORGAN TRANSPLANTATION;

EID: 9144264880     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2004.062_2.x     Document Type: Editorial

References (35)

1. FRASER TG, ZEMBOWER TR, LYNCH P, et al. Cavitary Legionella pneumonia in a liver transplant recipient. Transplant Infect Dis 2004: 6: 77-80.
2. MULAZIMOGLU L, YU VL. Can Legionnaires' disease be diagnosed by clinical criteria: a critical review. Chest 2001: 120: 1049-1053.
3. STOUT JE, RIHS JD, YU VL. Legionella. In: MURRAY PR, BARON EJ, JORGENSEN JH, PFALLER MA, YOLKEN RH, eds. Manual of Clinical Microbiology (8th edn). Washington, DC: ASM Press, 2003: 809-823.
4. RIHS JD, YU VL, ZURAVLEFF JJ, GOETZ A, MUDER RR. Isolation of Legionella pneumophila from blood with the BACTEC system: a prospective study yielding positive results. J Clin Microbiol 1985: 22: 422-424.
5. SOPENA N, SABRIA M, PEDRO-BOTET ML, et al. Factors related to persistence of Legionella urinary antigen excretion in patients with Legionnaires' disease. Eur J Clin Microbiol Infect Dis 2002: 21: 845-848.
6. VICKERS RM, YEE YC, RIHS JD, WAGENER MM, YU VL. Prospective assessment of sensitivity, quantitation, and timing of urinary antigen, serology, direct immunofluorescence (DFA) for diagnosis of Legionnaires' disease (LD). Abstracts Annual Meeting American Society for Microbiology, 1994: 493.
7. YU VL, PLOUFFE JF, CASTELLANI-PASTORIS M, et al. Distribution of Legionella species and serogroups isolated by culture in consecutive patients with community acquired pneumonia: an international collaborative survey. J Infect Dis 2002: 186: 127-128.
8. SABRIA M, GARCIA-NUNEZ M, PEDRO-BOTET ML, et al. Presence and chromosomal subtyping of Legionella spp in potable water systems in 20 hospitals of Catalonia, Spain. Infect Control Hosp Epidemiol 2002: 22: 673-676.
9. CHANG FY, JACOBS SL, COLODNY SM, STOUT JE, YU VL. Nosocomial Legionnaires' disease caused by Legionella pneumophila serogroup 5: laboratory and epidemiological implications. J Infect Dis 1996: 174: 1116-1119.
10. MEYER RD, EDELSTEIN PH, KIRBY BD, et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med 1980: 93: 240-243.
11. YU VL, GREENBERG RN, ZADEIKIS N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004: 125: 2135-2139.
12. BENIN AL, BENSON RF, BESSER RE. Trends in Legionnaires' disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002: 35: 1039-1046.
13. TAN JS, FILE TM JR, DIPERSIO LP, HAMOR R, SARAVOLATZ LD, STOUT JE. Persistently positive culture results in a patient with community-acquired pneumonia due to Legionella pneumophila. Clin Infect Dis 2001: 32: 1562-1566.
14. ONODY C, MATSIOTA-BERNARD P, NAUCIEL C. Lack of resistance to erythromycin, rifampin, and ciprofloxacin in 98 clinical isolates of Legionella pneumophila. J Antimicrob Chemother 1997: 39: 815-816.
15. STOUT JE, ARNOLD B, YU VL. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998: 41: 289-291.
16. CHRISTIANS U, GUENGERICH FP, SCHMIDT G, SEWING KF. In-vitro metabolism of FK506, cytochrome P450 and drug interactions. Ther Drug Monit 1993: 15: 145.
17. LAMPEN A, CHRISTIAN U, GUENGERICH FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995: 23: 1315-1324.
18. JENSEN C, JORDAN M, SHAPIRO R, et al. Interactions between tacrolimus and erythromycin [letter]. Lancet 1994: 344: 825.
19. FURLAN V, PARQUIN F, PENAUD JF, et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998: 30: 187-188.
20. WOLTER K, WAGNER K, PHILIPP T, FRITSCHKA E. Interaction between FK506 and clarithromycin in a renal transplant patient. Eur J Clin Pharmacol 1994: 47: 207-208.
21. AMACHER DE, SCHOMAKER SJ, RETSEMA JA. Comparison of the effects of the new azalide antibiotic, azithromycin and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991: 35: 1186-1190.
22. LJUTIC D, RUMBOLDT Z. Possible interaction between azithromycin and cyclosporin: a case report [letter]. Nephron 1995: 70: 130.
23. SAX A, DHARAN D, PITTET D. Legionnaires' disease in a renal transplant recipient: nosocomial or home grown? Transplantation 2002: 74: 890-892.
24. MARRIE TJ, BEZANSON G, HALDANE DJM, BURBRIDGE S. Colonization of the respiratory tract with Legionella pneumophila for 63 days before onset of pneumonia. J Infect 1992: 24: 81-86.
25. Centers for Disease Control and Prevention. Guidelines for environmental infection control in health-care facilities. Morbid Mortal Wkly Rep 2003: 52: 14-21.
26. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morbid Mortal Wkly Rep 2000: 49: 1-128.
27. YU VL. Resolving the controversy on environmental cultures for Legionella. Infect Control Hosp Epidemiol 1998: 19: 893-897.
28. BLATT SP, PARKINSON MD, PACE E, et al. Nosocomial Legionnaires' disease: aspiration as a primary mode of transmission. Am J Med 1993: 95: 16-22.
29. YU VL. Could aspiration be the major mode of transmission for Legionella? Am J Med 1993: 95: 13-15.
30. JOHNSON JT, YU VL, BEST M, et al. Nosocomial legionellosis uncovered in surgical patients with head and neck cancer: implications for epidemiologic reservoir and mode of transmission. Lancet 1985: 2: 298-300.
31. HELMS CM, MASSANARI RM, ZEITLER R, et al. Legionnaires' disease associated with a hospital water system: a cluster of 24 nosocomial cases. Ann Intern Med 1983: 99: 172-178.
32. STOUT JE, YU VL. Experiences of the first 16 hospitals using copper-silver ionization for Legionella control: implications for the evaluation of other disinfection modalities. Infect Control Hosp Epidemiol. 2003: 24: 563-468.
33. BEST M, YU VL, STOUT J, GOETZ A, MUDER RR, TAYLOR F. Legionellaceae in the hospital water supply - epidemiological link with disease and evaluation of a method of control of nosocomial Legionnaires' disease and Pittsburgh pneumonia. Lancet 1983: 2: 307-310.
34. KOOL JL, BERGMIRE-SWEAT D, BUTLER JC, et al. Hospital characteristics associated with colonization of water systems by Legionella and risk of nosocomial Legionnaires' disease: a cohort study of 15 hospitals. Infect Control Hosp Epidemiol 1999: 20: 798-805.
35. SINGH N, STOUT JE, YU VL. Legionnaires' disease in a renal transplant recipient acquired from the patient's home: implications for management. Transplantation 2002: 74: 755-756.